News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,617 Results
Type
Article (14899)
Company Profile (299)
Press Release (266413)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79836)
Career Advice (162)
Deals (13337)
Drug Delivery (39)
Drug Development (50699)
Employer Resources (31)
FDA (5836)
Job Trends (5167)
News (145076)
Policy (10071)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21761)
ALS (125)
Alzheimer's disease (1032)
Antibody-drug conjugate (ADC) (241)
Approvals (6031)
Artificial intelligence (259)
Autoimmune disease (114)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (344)
Cancer (3130)
Cardiovascular disease (237)
Career advice (147)
Career pathing (7)
CAR-T (219)
CDC (5)
Cell therapy (565)
Cervical cancer (14)
Clinical research (43671)
Collaboration (1151)
Company closure (2)
Compensation (596)
Complete response letters (39)
COVID-19 (1100)
CRISPR (86)
C-suite (553)
Cystic fibrosis (112)
Data (4325)
Denatured (15)
Depression (92)
Diabetes (255)
Diagnostics (1379)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (188)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (216)
Earnings (31646)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51668)
Executive appointments (622)
FDA (7590)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (982)
Gene editing (182)
Generative AI (21)
Gene therapy (490)
GLP-1 (504)
Government (1147)
Grass and pollen (3)
Guidances (166)
Healthcare (6611)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (40)
Indications (66)
Infectious disease (1205)
Inflammatory bowel disease (156)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7345)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (244)
Leadership (9)
Legal (1400)
Liver cancer (41)
Longevity (11)
Lung cancer (420)
Lymphoma (249)
Machine learning (24)
Management (7)
Manufacturing (376)
MASH (130)
Medical device (2662)
Medtech (2671)
Mergers & acquisitions (6616)
Metabolic disorders (725)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (231)
Neuropsychiatric disorders (70)
Neuroscience (1954)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (865)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (330)
Peanut (43)
People (26655)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15475)
Phase 2 (20291)
Phase 3 (12821)
Pipeline (3263)
Policy (90)
Postmarket research (853)
Preclinical (6535)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (651)
Real estate (1448)
Recruiting (12)
Regulatory (9899)
Reports (19)
Research institute (971)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (183)
Series B (136)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2005)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (334)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Today (55)
Last 7 days (325)
Last 30 days (1168)
Last 365 days (17850)
2026 (1705)
2025 (18098)
2024 (20543)
2023 (22414)
2022 (26823)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18255)
Australia (3111)
California (7079)
Canada (1839)
China (774)
Colorado (247)
Connecticut (252)
Delaware (235)
Europe (39168)
Florida (903)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (161)
Iowa (8)
Japan (224)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5588)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1648)
New Mexico (13)
New York (1763)
North Carolina (827)
North Dakota (6)
Northern California (3477)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1280)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2808)
Tennessee (40)
Texas (907)
United States (23351)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,617 Results for "neubase therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
NeuBase Therapeutics Announces Receipt of Notice from Nasdaq - April 05, 2024
NeuBase Therapeutics, Inc. reported that it received a notice on April 4, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250 as a result of its failure to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 in a timely manner.
April 5, 2024
·
2 min read
Deals
NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation (“Symetryx”) and their subsequent press release issued on September 6, 2023.
September 8, 2023
·
3 min read
Pharm Country
NeuBase Therapeutics to Explore Strategic Alternatives
NeuBase Therapeutics, Inc., a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, announced that its Board of Directors has completed a review of the Company’s business, including the status of its programs, resources, and capabilities.
August 3, 2023
·
3 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
Pharm Country
NeuBase to Participate in Jefferies 2023 Healthcare Conference
NeuBase Therapeutics, Inc. announced that the Company’s management will participate in the Jefferies Healthcare Conference being held at the Marriott Marquis in New York, NY on June 7-9, 2023.
May 24, 2023
·
4 min read
Business
NeuBase Reports Business Update and Financial Results for the First Quarter of 2023
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today reported its financial results for the three-month period ended March 31, 2023 and other recent developments.
May 11, 2023
·
7 min read
Business
NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the three-month period ended December 31, 2022, and other recent developments.
February 14, 2023
·
6 min read
Business
NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022
NeuBase Therapeutics, Inc. today reported its financial results for the fiscal year ended September 30, 2022, and other recent developments.
December 21, 2022
·
9 min read
Business
NeuBase Announces Formation of Gene Editing Advisory Board
NeuBase Therapeutics, Inc. announced the formation of a gene editing advisory board comprised of distinguished leaders of the scientific community who will support the development of the differentiated gene editing capabilities of the Company’s PATrOL™ platform.
May 16, 2023
·
11 min read
Pharm Country
NeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced two abstracts have been accepted for two oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting.
May 2, 2023
·
4 min read
1 of 28,162
Next